Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

January 31, 2018

Study Completion Date

July 31, 2018

Conditions
Kawasaki Disease
Interventions
DRUG

Atorvastatin

Atorvastatin dose titration to maximum tolerated dose (once daily for 6 weeks)

Trial Locations (1)

92093

University of California San Diego, San Diego

All Listed Sponsors
collaborator

Children's Hospital Colorado

OTHER

collaborator

University of Colorado, Denver

OTHER

lead

University of California, San Diego

OTHER

NCT01431105 - Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities | Biotech Hunter | Biotech Hunter